Development of PI3Kγ selective inhibitors: the strategies and application

被引:0
|
作者
Dong-yan Gu
Meng-meng Zhang
Jia Li
Yu-bo Zhou
Rong Sheng
机构
[1] Zhejiang University,College of Pharmaceutical Sciences
[2] State Key Laboratory of Drug Research,National Center for Drug Screening
[3] Shanghai Institute of Materia Medica,undefined
[4] Chinese Academy of Sciences,undefined
来源
关键词
PI3K; PI3Kγ inhibitors; isoform selectivity; drug development; rational drug design;
D O I
暂无
中图分类号
学科分类号
摘要
The γ isoform of Class I PI3Ks (PI3Kγ) is primarily found in leukocytes and is essential for the function of myeloid cells, as it regulates the migration, differentiation, and activation of myeloid-lineage immune cells. Thus, PI3Kγ has been identified as a promising drug target for the treatment of inflammation, autoimmune disease, and immuno-oncology. Due to the high incidence of serious adverse events (AEs) associated with PI3K inhibitors, in the development of PI3Kγ inhibitors, isoform selectivity was deemed crucial. In this review, an overview of the development of PI3Kγ selective inhibitors in the past years is provided. The isoform selectivity of related drugs was achieved by different strategies, including inducing a specificity pocket by a propeller-shape structure, targeting steric differences in the solvent channel, and modulating the conformation of the Asp-Phe-Gly DFG motif, which have been demonstrated feasible by several successful cases. The insights in this manuscript may provide a potential direction for rational drug design and accelerate the discovery of PI3Kγ selective inhibitors.
引用
收藏
页码:238 / 247
页数:9
相关论文
共 50 条
  • [1] Development of PI3Kγ selective inhibitors: the strategies and application
    Gu, Dong-Yan
    Zhang, Meng-Meng
    Li, Jia
    Zhou, Yu-Bo
    Sheng, Rong
    [J]. ACTA PHARMACOLOGICA SINICA, 2024, 45 (02) : 238 - 247
  • [2] Development of novel, selective and irreversible PI3Kδ inhibitors
    Dalton, Samuel
    Campos, Sebastien
    Bush, Jacob
    Thomas, Daniel
    Convery, Maire
    Murphy, John
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [3] Development of Scalable Syntheses of Selective PI3K inhibitors
    Huang, Qinhua
    Richardson, Paul F.
    Sach, Neal W.
    Zhu, Jinjiang
    Liu, Kevin K-C.
    Smith, Graham L.
    Bowles, Daniel M.
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2011, 15 (03) : 556 - 564
  • [4] Designing selective PI3K inhibitors
    Sarah Crunkhorn
    [J]. Nature Reviews Drug Discovery, 2010, 9 : 105 - 105
  • [5] Designing selective PI3K inhibitors
    Crunkhorn, Sarah
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 105 - 105
  • [6] The development of inhibitors of PI3K and Akt
    Dennis, PA
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [7] Clinical development of inhibitors of the PI3K
    Saura Manich, C.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [8] PI3K inhibitors: review and new strategies
    Zhang, Mingzhen
    Jang, Hyunbum
    Nussinov, Ruth
    [J]. CHEMICAL SCIENCE, 2020, 11 (23) : 5855 - 5865
  • [9] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
  • [10] Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors
    Ma, Chen-Chen
    Zhang, Cheng-Mei
    Tang, Long-Qian
    Liu, Zhao-Peng
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 9 - 17